Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs – Webcourse

Format: Webcourse

Credit(s): 1.00 (60 min)

Release Date: Dec 20, 2022

Expiration Date: Dec 19, 2023

Credit Type(s):

MIPS Improvement Activity Under MACRA
Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABIM MOC – ABIM MOC Point(s)
Nurses – Contact Hour(s)

PROGRAM OVERVIEW

Anemia in CKD is associated with increased risk of CKD progression, poor CV outcomes, decreased health-related quality of life, and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events.

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs will familiarize nephrology clinicians with the etiology of anemia in CKD, the effects on health outcomes, quality of life, and function, advantages and limitations of current management strategies and the economic advantages of their use, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia.